Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study

What Was Tested

Researchers studied Exenatide in this randomized controlled trial publication.

Who Took Part

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

Patients aged >or=18 years with type 2 diabetes were randomly assigned to receive exenatide 5 microg, exenatide 10 microg, or placebo administered SC BID.

Patients were instructed by investigators to maintain their individualized prestudy diet and exercise regimens throughout the study.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and parallel-group study.

Because people in this Exenatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Exenatide.

Some participants received a placebo instead of Exenatide, giving a reference point.

The Exenatide group and the comparison group ran side by side rather than switching.

This 24-week, double-blind, placebo-controlled, parallel-group study was conducted at 23 centers across the United States, Puerto Rico, Romania, Russia, and India.

Tolerability measures included patient-reported adverse events, hypoglycemia, and blood pressure.

What Was Measured

PubMed files the paper under topics including Blood Glucose, Blood Pressure, Body Mass Index, Diabetes Mellitus, Type 2, Exenatide, Glycated Hemoglobin and Hypoglycemia.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exenatide.

Its findings take up roughly 14 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2008 (Clinical therapeutics), a journal based in United States.

More context: the Exenatide compound page.